Leukapheresis Market Size Worth USD 199.38 Million By 2034 | CAGR: 8.8%

The global leukapheresis market size is expected to reach USD 199.38 million by 2034, according to a new study by Polaris Market Research. The report “Leukapheresis Market Share, Size, Trends, Industry Analysis Report: By Type, By Leukopak, By Indication, By Application (Research and Therapeutics), By End-Use, and By Region – Segment Forecasts, 2026–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Leukapheresis is a laboratory-based method for separating white blood cells from a blood sample. It is a type of apheresis procedure that involves separating one specific blood constituent and returning the remainder to the bloodstream. Previously, the leukapheresis method was designed for the palliative treatment of diseases such as leukemia with minimal efficacy. But later, it was also adopted for the treatment modality for hyperleukocytosis in acute myeloid leukemia.

An increasing number of populations suffering from leukemia, rising numbers of blood donation centers, and government spending on improving healthcare infrastructure, along with R&D and clinical trials focused on leukocytes and CAR-T cells to treat various other cancer types, are key factors driving market growth.

The procedure removes WBCs, including leukemia cells, and returns the remaining blood cell components to the circulatory system. The increasing incidence of leukemia and the surge in cases of associated disorders are likely to intensify industry growth over the study period. The demand for this industry is projected to grow in the near future due to rising research and development activities on leukocytes, the increasing number of blood donations & surging demand for leukopaks.

Leukapheresis Market Report Highlights

• The leukapheresis device segment accounted for the largest market share. This is driven by the increasing adoption of advanced cell separation technologies.
• The research application is expected to account for the highest CAGR during the forecast period, driven by growing focus on personalized medicine.
• The blood component providers and blood centers segment is projected to account for the fastest growth over the projection period, driven by rising demand for leukocyte-depleted blood components.
• North America dominated the leukapheresis market. The regional market is driven by growing healthcare infrastructure and high clinical trial activity.
• The Asia Pacific leukapheresis market is anticipated to witness the fastest growth. The rise in clinical trials and investments in oncology and advanced therapies is driving the adoption of leukapheresis capabilities in the region.
• A few of the major market participants include AllCells, LLC, StemExpress, LLC., Haemonetics Corporation, Caltag Medsystems Limited, Lonza Group AG, ZenBio, Asahi Kasei Medical, Terumo BCT, Inc., Macopharma SA, Miltenyi Biotec, Fresenius SE & Co. KGaA, Guangzhou Daji Medical Science, MEDICA S.p.A, PuriBlood Medical Co. Ltd., and Beijing ZKSK Technology Co. Ltd.

Where is the Market Headed?

The market is shifting towards steady, long-term growth, driven by rising demand for radiation oncology, advanced cancer treatment solutions, and the acceptance of personalized care. There is a greater focus among healthcare service providers on improving treatment outcomes, which is increasing demand for cell collection facilities. With increased investment in oncology treatment, improved treatment centers, and enhanced accessibility of specialized solutions in emerging nations, the market is likely to gain momentum. In the coming years, the market is likely to benefit from increased awareness, improved service availability, and greater cooperation among hospitals, blood centers, and therapy developers to create an efficient market system.

What Does Leukapheresis Report Reveals?

• What is the global market size and CAGR for the market during 2026–2034?
• Which factors are contributing to the industry expansion?
• Who are the key industry players? What is their relative position in terms of competitive positioning?
• How do different applications, such as research and therapeutics, influence the market landscape?
• How does the market differ in terms of type, leukopak, indication, application, end-use, and geography? Which is the leading end-use?
• What are the opportunities in different regional markets, including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa?
• What are the emerging technologies and innovations in the market?

Request a free sample copy or read the full market insights :  leukapheresis market Report

Polaris Market Research has segmented the leukapheresis market report on the basis of type, leukopak, indication, application, end-use, and region:

By Type Outlook (Revenue, USD Million, 2021–2034)

• Devices
  • Apheresis Devices
  • Columns & Cell Separators
  • Leuko-reduction Filters
• Disposables

By Leukopak Outlook (Revenue, USD Million, 2021–2034)

• Mobilized Leukopaks
• Non-Mobilized Leukopaks
• Diseased Leukopaks
• Peripheral Blood Mononuclear Cells (Pbmc)

By Indication Outlook (Revenue, USD Million, 2021–2034)

• Leukemia
  • AML
  • ALL
  • CLL
• Lymphoma
• Multiple Myeloma

By Application Outlook (Revenue, USD Million, 2021–2034)

• Research
• Therapeutic

By End-Use Outlook (Revenue, USD Million, 2021–2034)

• Blood Component Providers and Blood Centers
• Academic and Research Institutes
• Pharmaceutical and Biotechnology Companies
• Hospitals and Transfusion Centers

By Regional Outlook (Revenue, USD Million, 2021–2034)

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America